Publications

Detailed Information

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer

DC Field Value Language
dc.contributor.authorLee, H. J.-
dc.contributor.authorSeo, A. N.-
dc.contributor.authorKim, E. J.-
dc.contributor.authorJang, M. H.-
dc.contributor.authorKim, Y. J.-
dc.contributor.authorKim, J. H.-
dc.contributor.authorKim, S. -W.-
dc.contributor.authorRyu, H. S.-
dc.contributor.authorPark, I. A.-
dc.contributor.authorIm, S. -A.-
dc.contributor.authorGong, G.-
dc.contributor.authorJung, K. H.-
dc.contributor.authorKim, H. J.-
dc.contributor.authorPark, S. Y.-
dc.date.accessioned2022-03-22T09:22:11Z-
dc.date.available2022-03-22T09:22:11Z-
dc.date.created2018-10-01-
dc.date.created2018-10-01-
dc.date.issued2015-01-
dc.identifier.citationBritish Journal of Cancer, Vol.112 No.1, pp.103-111-
dc.identifier.issn0007-0920-
dc.identifier.other57147-
dc.identifier.urihttps://hdl.handle.net/10371/177268-
dc.description.abstractBackground: Epidermal growth factor receptor (EGFR) is overexpressed in a subset of human epidermal growth factor receptor 2 (HER2)-positive breast cancers, and coexpression of HER2 and EGFR has been reported to be associated with poor clinical outcome. Moreover, interaction between HER2 and EGFR has been suggested to be a possible basis for trastuzumab resistance. Methods: We analysed the clinical significance of EGFR overexpression and EGFR gene copy number alterations in 242 HER2-positive primary breast cancers. In addition, we examined the correlations between EGFR overexpression, trastuzumab response and clinical outcome in 447 primary, and 112 metastatic HER2-positive breast cancer patients treated by trastuzumab. Results: Of the 242 primary cases, the level of EGFR overexpression was 2+ in 12.7% and 3+ in 11.8%. High EGFR gene copy number was detected in 10.3%. Epidermal growth factor receptor overexpression was associated with hormone receptor negativity and high Ki-67 proliferation index. In survival analyses, EGFR overexpression, but not high EGFR copy number, was associated with poor disease-free survival in all patients, and in the subgroup not receiving adjuvant trastuzumab. In 447 HER2-positive primary breast cancer patients treated with adjuvant trastuzumab, EGFR overexpression was also an independent poor prognostic factor. However, EGFR overexpression was not associated with trastuzumab response, progression-free survival or overall survival in the metastatic setting. Conclusions: Epidermal growth factor receptor overexpression, but not high EGFR copy number, is a poor prognostic factor in HER2-positive primary breast cancer. Epidermal growth factor receptor overexpression is a predictive factor for trastuzumab response in HER2-positive primary breast cancer, but not in metastatic breast cancer.-
dc.language영어-
dc.publisherNature Publishing Group-
dc.titlePrognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor임석아-
dc.identifier.doi10.1038/bjc.2014.556-
dc.citation.journaltitleBritish Journal of Cancer-
dc.identifier.wosid000348280900016-
dc.identifier.scopusid2-s2.0-84920686176-
dc.citation.endpage111-
dc.citation.number1-
dc.citation.startpage103-
dc.citation.volume112-
dc.identifier.sci000348280900016-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorKim, J. H.-
dc.contributor.affiliatedAuthorPark, I. A.-
dc.contributor.affiliatedAuthorIm, S. -A.-
dc.contributor.affiliatedAuthorPark, S. Y.-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusGROWTH-FACTOR RECEPTOR-
dc.subject.keywordPlusGENE AMPLIFICATION-
dc.subject.keywordPlusPROTEIN EXPRESSION-
dc.subject.keywordPlusTRASTUZUMAB-
dc.subject.keywordPlusHER2-
dc.subject.keywordPlusCARCINOMAS-
dc.subject.keywordPlusGEFITINIB-
dc.subject.keywordPlusSENSITIVITY-
dc.subject.keywordPlusRESISTANCE-
dc.subject.keywordPlusHERCEPTIN-
dc.subject.keywordAuthorbreast carcinoma-
dc.subject.keywordAuthorgene amplification-
dc.subject.keywordAuthorEGFR-
dc.subject.keywordAuthorHER2-
dc.subject.keywordAuthortrastuzumab-
dc.subject.keywordAuthorimmunohistochemistry-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Clinical Medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share